158 related articles for article (PubMed ID: 15655407)
1. Ibandronate in metastatic bone disease: a review of preclinical data.
Bauss F; Body JJ
Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
3. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Magnetto S; Boissier S; Delmas PD; Clezardin P
Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Heidenreich A; Ohlmann CH
Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
7. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
9. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
[TBL] [Abstract][Full Text] [Related]
10. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
Pecherstorfer M
Expert Opin Pharmacother; 2008 Dec; 9(17):3111-9. PubMed ID: 19006482
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
14. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for the prevention of bone metastases.
Coleman RE
Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
17. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate in metastatic bone pain.
Heidenreich A; Ohlmann C; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
[TBL] [Abstract][Full Text] [Related]
19. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate reduces skeletal morbidity in patients with breast cancer.
Tripathy A D; Diel I; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]